A research brief from the Innovation and Value Initiative (IVI) took a look at how accounting for patients’ attitudes towards risks in treatment outcomes affects value.
A research brief from the Innovation and Value Initiative (IVI) took a look at how accounting for patients’ attitudes towards risks in treatment outcomes affects value. Focusing on non-small cell lung cancer (NSCLC), the brief used the IVI-NSCLC model, an open-source simulation model that assesses the costs, benefits, and risks of sequences of treatment for EGFR-mutated disease. The model also includes an experimental module for calculating the value of hope, which has been suggested as one of the elements to augment conventional cost-effectiveness analysis.
Costs and outcomes for 2 possible treatment sequences were determined and the value of hope was added to the quality-adjusted life years (QALYs) by estimating the QALYs a patient would need to obtain to be indifferent toward the 2 sequences of treatment.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen